Logo image of TCM.MI

TECMA SOLUTIONS SPA (TCM.MI) Stock Fundamental Analysis

BIT:TCM - Euronext Milan - IT0005425050 - Common Stock - Currency: EUR

1.42  +0.06 (+4.41%)

Fundamental Rating

2

TCM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Real Estate Management & Development industry. TCM may be in some trouble as it scores bad on both profitability and health. TCM is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TCM had negative earnings in the past year.
TCM had a positive operating cash flow in the past year.
TCM had negative earnings in 4 of the past 5 years.
In the past 5 years TCM reported 4 times negative operating cash flow.
TCM.MI Yearly Net Income VS EBIT VS OCF VS FCFTCM.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M

1.2 Ratios

TCM has a Return On Assets of -29.76%. This is amonst the worse of the industry: TCM underperforms 90.14% of its industry peers.
TCM has a Return On Equity of -97.98%. This is amonst the worse of the industry: TCM underperforms 87.32% of its industry peers.
Industry RankSector Rank
ROA -29.76%
ROE -97.98%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCM.MI Yearly ROA, ROE, ROICTCM.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

TCM has a better Gross Margin (73.19%) than 69.01% of its industry peers.
In the last couple of years the Gross Margin of TCM has declined.
TCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.85%
GM growth 5Y-2.55%
TCM.MI Yearly Profit, Operating, Gross MarginsTCM.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

TCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCM.MI Yearly Shares OutstandingTCM.MI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
TCM.MI Yearly Total Debt VS Total AssetsTCM.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

TCM has an Altman-Z score of -0.52. This is a bad value and indicates that TCM is not financially healthy and even has some risk of bankruptcy.
TCM's Altman-Z score of -0.52 is on the low side compared to the rest of the industry. TCM is outperformed by 83.10% of its industry peers.
TCM has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.02, TCM is doing worse than 66.20% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF N/A
Altman-Z -0.52
ROIC/WACCN/A
WACC6.62%
TCM.MI Yearly LT Debt VS Equity VS FCFTCM.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 1.81 indicates that TCM should not have too much problems paying its short term obligations.
The Current ratio of TCM (1.81) is comparable to the rest of the industry.
TCM has a Quick Ratio of 1.81. This is a normal value and indicates that TCM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.81, TCM is in the better half of the industry, outperforming 69.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.81
TCM.MI Yearly Current Assets VS Current LiabilitesTCM.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M

More info and screens

4

3. Growth

3.1 Past

TCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.21%, which is quite impressive.
TCM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.00%.
Measured over the past years, TCM shows a very strong growth in Revenue. The Revenue has been growing by 26.75% on average per year.
EPS 1Y (TTM)74.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.32%
Revenue 1Y (TTM)14%
Revenue growth 3Y11.91%
Revenue growth 5Y26.75%
Sales Q2Q%3.54%

3.2 Future

TCM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.50% yearly.
The Revenue is expected to decrease by -12.24% on average over the next years. This is quite bad
EPS Next Y32.38%
EPS Next 2Y20.7%
EPS Next 3Y13.5%
EPS Next 5YN/A
Revenue Next Year2.83%
Revenue Next 2Y-16.37%
Revenue Next 3Y-12.24%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TCM.MI Yearly Revenue VS EstimatesTCM.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
TCM.MI Yearly EPS VS EstimatesTCM.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 7.06 indicates a rather cheap valuation of TCM.
Based on the Price/Forward Earnings ratio, TCM is valued cheaply inside the industry as 90.14% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 36.21. TCM is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.06
TCM.MI Price Earnings VS Forward Price EarningsTCM.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCM.MI Per share dataTCM.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

TCM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TCM's earnings are expected to grow with 13.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.7%
EPS Next 3Y13.5%

More info and screens

0

5. Dividend

5.1 Amount

TCM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TECMA SOLUTIONS SPA

BIT:TCM (7/24/2025, 7:00:00 PM)

1.42

+0.06 (+4.41%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners7.69%
Inst Owner ChangeN/A
Ins Owners43.53%
Ins Owner ChangeN/A
Market Cap12.23M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.06
P/S 0.89
P/FCF N/A
P/OCF 90.5
P/B 2.65
P/tB 26.5
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.2
Fwd EY14.16%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)0.02
OCFY1.11%
SpS1.6
BVpS0.54
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.76%
ROE -97.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.19%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.85%
GM growth 5Y-2.55%
F-Score5
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.15%
Cap/Sales 10.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.81
Altman-Z -0.52
F-Score5
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.32%
EPS Next Y32.38%
EPS Next 2Y20.7%
EPS Next 3Y13.5%
EPS Next 5YN/A
Revenue 1Y (TTM)14%
Revenue growth 3Y11.91%
Revenue growth 5Y26.75%
Sales Q2Q%3.54%
Revenue Next Year2.83%
Revenue Next 2Y-16.37%
Revenue Next 3Y-12.24%
Revenue Next 5YN/A
EBIT growth 1Y51.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year237.87%
EBIT Next 3Y32.93%
EBIT Next 5YN/A
FCF growth 1Y83.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.76%
OCF growth 3YN/A
OCF growth 5YN/A